Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Trukera Medical, whose executive chairman is well-known Orange County executive Jim Mazzo, announced last month that it has been acquired by global eye health company Bausch + Lomb Corp. for an ...

Bausch + Lomb rose in premarket trading Monday after the Financial Times reported that it is considering selling itself as a way to separate from Bausch Health, its indebted parent company. Shares ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

With U.S. stock markets set to open in two hours, Nuvalent Inc. Cl A (NUVL) was up 17.2% in pre-market trading, and Bausch + Lomb Corp. (BLCO) was up 15.8%.